mdma
(2)
Sam Clark
Sam Clark, MD, PhD, is the founder and CEO of Terran Biosciences, a CNS-focused platform biotech he started in 2017 from his medical school dorm room with $10,000. A neuroscientist trained at MIT and Columbia, Clark has built one of the largest psychedelic development programs in the industry, is the named inventor on more than 200 patent applications, and holds the world's first patents for new forms of psilocybin and MDMA. Terran pairs a medicinal-chemistry drug design engine with an FDA-cleared neuroimaging software platform and a pipeline of late-stage assets licensed from Sanofi and Pierre Fabre.
Terran Biosciences
Terran Biosciences is a platform biotech developing therapeutics and technologies for neurological and psychiatric disease. It runs one of the industry's largest psychedelic development programs - psilocybin, LSD, MDMA derivatives and novel prodrugs - alongside late-stage schizophrenia assets licensed from Sanofi and Pierre Fabre, GMP psychedelic manufacturing, and NM-101, an FDA-cleared cloud platform for neuromelanin MRI analysis.